Pierre Blanchard

Tübingen Hoppe Seyler Str. 3
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 322 publications

How to optimise prostate SBRT: ESTRO clinical practice consensus recommendations.

How to optimise prostate SBRT: ESTRO clinical practice consensus recommendations.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: July 07, 2026

Five-Year Patient-Reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?

Five-Year Patient-Reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?

Journal: European urology

Published: June 30, 2026

PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

Journal: European urology oncology

Published: June 03, 2026

Sharing expertise, shaping excellence: The Green technical vision (GTV), a new section in the Green Journal.

Sharing expertise, shaping excellence: The Green technical vision (GTV), a new section in the Green Journal.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: May 05, 2026

Hot flushes during ADT for prostate cancer - a clinical rationale for a neurokinin 3 receptor antagonist.

Hot flushes during ADT for prostate cancer - a clinical rationale for a neurokinin 3 receptor antagonist.

Journal: Nature reviews. Urology

Published: April 28, 2026

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Journal: Cancer treatment reviews

Published: April 28, 2026

Impact of HPV status on the occurrence of osteoradionecrosis in patients with oropharyngeal carcinoma treated with definitive radiotherapy or chemoradiotherapy.

Impact of HPV status on the occurrence of osteoradionecrosis in patients with oropharyngeal carcinoma treated with definitive radiotherapy or chemoradiotherapy.

Journal: Journal of stomatology, oral and maxillofacial surgery

Published: April 10, 2026

Integration of radiation therapy with systemic treatments in head and neck cancer: expert opinion and roadmap to consensus.

Integration of radiation therapy with systemic treatments in head and neck cancer: expert opinion and roadmap to consensus.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: March 30, 2026

HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.

HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 18, 2026

Erratum to "External beam radiotherapy for prostatic cancers: 2025 update" [Cancer Radiother 29 (2025) 104777].

Erratum to "External beam radiotherapy for prostatic cancers: 2025 update" [Cancer Radiother 29 (2025) 104777].

Journal: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Published: February 17, 2026

Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology.

Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology.

Journal: The Lancet. Oncology

Published: February 13, 2026

Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers: The STEREOPOSTOP-GORTEC 2017-03 Nonrandomized Clinical Trial.

Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers: The STEREOPOSTOP-GORTEC 2017-03 Nonrandomized Clinical Trial.

Journal: JAMA network open

Published: February 03, 2026

Showing 1-12 of 322

Last Updated: 09/26/2026